44 results
8-K
EX-10.1
BTAX
Biostax Corp.
12 Oct 22
Entry into a Material Definitive Agreement
8:49am
package if the sublicense occurs before completing a clinical trial, 10% if the sublicence occurs after completing any trial, and 5% if sublicense
8-K
EX-10.1
fs439pvb
27 Jul 20
Departure of Directors or Certain Officers
3:07pm
8-K
EX-10.1
rpi2w1
20 Mar 20
Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19
11:43am
8-K
o0pfvf
25 Sep 19
Entry into a Material Definitive Agreement
5:05pm
8-K
EX-10.1
08db5ujrg2gvw96h 0bg
25 Sep 19
Entry into a Material Definitive Agreement
5:05pm